BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP.

As of September 30, 2011, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. carries a market capitalization of 1.89M, placing it among publicly traded companies globally. Its enterprise value stands at 2.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2011, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. has 944,113.00 shares outstanding.

These figures are as of September 30, 2011. The price-to-sales ratio is -5.61, and the price-to-book ratio stands at -1.17.

As of September 30, 2011, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. trades at an EV/EBITDA multiple of 6.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. Its EV/EBIT multiple of 7.70 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.41M versus a market cap of 1.89M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2011, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. maintains a current ratio of - -, meaning it holds the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -32.31, indicating conservative leverage, while an interest coverage ratio of 3.69 demonstrates adequate ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2011. Return on assets (ROA) is negative at -42.88, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 4.67, useful for judging operating efficiency across full business cycles. The company generates approximately -8,515.82 in revenue per employee across its workforce of 38.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP.'s stock has gained approximately 149350.00% over the past 52 weeks. The 50-day moving average sits at 0.23, while the 200-day moving average is 0.78.

Over the twelve months ended September 30, 2011, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. generated -323,601.00 in revenue and converted that into -130,018.00 in net income, yielding earnings per share of 0.23. EBITDA reached 388,003.00, while operating income came in at 312,250.00.

As of September 30, 2011, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. holds - - in cash and equivalents against 521,019.00 in total debt, resulting in a net debt position of 415,799.00. Total book value stands at -1.61M, with working capital of -1.56M providing operational flexibility.

BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. produced -196,698.00 in operating cash flow over the twelve months ended September 30, 2011. After subtracting - - in capital expenditures, free cash flow totaled -196,698.00 - equivalent to -0.22 per share.

Over the twelve months ended September 30, 2011, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. posted a gross margin of -65.54, reflecting its pricing power and cost economics. The operating margin of -96.49 and net profit margin of 40.18 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2011. Free cash flow yield is negative at -10.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.42, meaning BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP.'s most recent stock split took place on December 24, 2018 with a 20:1 split ratio.

As of September 30, 2011, BJ BIO-TECH DEVELOPMENT MANAGEMENT GROUP HOLDING CORP. has an Altman Z-Score of -247.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.